{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-010098","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.055370+00:00","generated_at":"2026-06-05T09:01:12.428126+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Immunocore FY2023 KIMMTRAK sales $238.7M; launches PRAME Phase 3 with BMS","bullets":["Q4 2023 KIMMTRAK net sales $67.6M; full year $238.7M (+12% YoY). US $169.8M, Europe $67.6M.","Net loss FY2023 $55.3M ($1.13 loss per share) vs $52.5M in 2022. R&D $163.5M, SG&A $144.5M.","Cash $442.6M at Dec 31; raised $389.3M net in Feb 2024 via 2.5% convertible notes due 2030.","Entered collaboration with BMS for Phase 3 PRISM-MEL301 trial of IMC-F106C + nivolumab in 1L advanced melanoma; first patient Q1 2024.","Multiple PRAME data readouts in 2024: cutaneous melanoma (Q2), ovarian (Q3), NSCLC (Q4). KIMMTRAK now in 12 launched countries."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-010098","json":"https://secwatch.observer/filing/0001140361-24-010098.json","markdown":"https://secwatch.observer/filing/0001140361-24-010098.md","text":"https://secwatch.observer/filing/0001140361-24-010098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124010098/0001140361-24-010098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124010098/ef20022689_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:01:12.428126+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}